Skip to content

Ketamine: all studies

Page 128 of 449: studies 1,271 to 1,280 of 4,486, newest first. Back to the ketamine overview

Research

Transient peripheral blood transcriptomic response to ketamine treatment in children with ADNP syndrome.

Translational Psychiatry July 25, 2024 Ariela S. Buxbaum Grice, Laura G Sloofman, Tess Levy et al. 3 citations

Activity-dependent neuroprotective protein (ADNP) syndrome is a rare neurodevelopmental disorder resulting in intellectual disability, developmental delay and autism spectrum disorder (ASD) and is due to mutations in the ADNP gene. Ketamine treatment has emerged as a promising therapeutic option for ADNP syndrome, showing safety and apparent behavioral improvements in a first open label study....

A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.

BMC Psychiatry July 18, 2024 Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al. 11 citations

Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent pain management...

DOI: 10.1186/s12888-024-05951-5 (opens in new tab) Full text (opens in new tab) Response Tolerability Depression treatment Ketamine therapy +3

Effect of ketamine enantiomers and maternal deprivation on depressive-like behavior and plasma concentration of BDNF in rats

Research, Society and Development July 15, 2024 G. Beanes, Beatriz A Carneiro, G. Marques et al.

Background: Low doses of different ketamine enantiomers have demonstrated rapid behavioural and biological actions in animals with depressive-like behavior. However, some authors report different effects depending on model of depression and ketamine isomer used. Objective: Our primary aim was to evaluate the effect of ketamine enantiomers on depressive-like behavior, anhedonic-like behavior and...

Long-term follow-up of participants in ketamine clinical trials for mood disorders.

Journal of Affective Disorders July 15, 2024 Kelly T Hurst, Abigail Vogeley, Deanna K Greenstein et al. 8 citations

Participants who received ketamine at the NIMH were among the first to receive ketamine for depression in controlled clinical trials, providing a unique opportunity to assess long-term outcomes. This analysis evaluated the relationship between participating in a ketamine clinical trial and subsequent ketamine/esketamine use after leaving the research setting. Participants seen within the NIMH...

DOI: 10.1016/j.jad.2024.04.062 (opens in new tab) Full text (opens in new tab) Esketamine Clinical trials Clinical-trials Depression-treatment +3

Esketamine in depression: putative biomarkers from clinical research.

European Archives of Psychiatry and Clinical Neuroscience July 13, 2024 Jenessa N Johnston, Carlos A. Zarate, Mark D Kvarta 18 citations

The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant depression (TRD) are significant advances in the development of novel neuropsychiatric therapeutics. Esketamine is now recognized as a powerful tool for addressing persistent symptoms of TRD compared to traditional oral...

DOI: 10.1007/s00406-024-01865-1 (opens in new tab) Full text (opens in new tab) Spravato Mechanism of action Suicide Treatment-resistant depression trd +6

Nitric Oxide Donor Sodium Nitroprusside Reduces Racemic Ketamine-But Not Esketamine-Induced Pain Relief.

ACS Pharmacology & Translational Science July 12, 2024 Albert Dahan, Simone C Jansen, Rutger van der Schrier et al. 8 citations

The anesthetic, analgesic and antidepressant drug ketamine produces dissociation with symptoms of psychosis and anxiety, an effect attributed to neuronal nitric oxide depletion following N-methyl-d-aspartate blockade. There is evidence that dissociation induced by racemic ketamine, containing both ketamine enantiomers (S- and R-ketamine) but not esketamine (the S-isomer) is inhibited by nitric...

DOI: 10.1021/acsptsci.4c00133 (opens in new tab) Full text (opens in new tab) Ketamine research Pain medication Blood pressure drugs Pharmacology +1

Electroencephalography and Magnetoencephalography Signatures of Ketamine Treatment in Depression: A Literature Review

Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal July 11, 2024 Eva M. Geoghegan

Introduction: Ketamine has been shown to have rapid antidepressant effects. In addition, the use of EEG in depression offers a new approach to diagnose patients. It is necessary to understand locational-based EEG and MEG changes following ketamine in patients with depression to establish a potential biomarker panel. This study sought to identify consistent changes in band power as well as to...

Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions

Journal of Anesthesia and Translational Medicine July 11, 2024 Kenji Hashimoto, Mingming Zhao, Tingting Zhu et al. 32 citations

Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, is similarly employed for anesthesia and analgesia. The anesthetic effects of both ketamine and esketamine arise from their antagonism of the N-methyl-D-aspartate receptor (NMDAR). In field of psychiatry, the rapid-acting antidepressant properties of ketamine for...

The effectiveness of ketamine in medication of treatment-resistant depression - review

Quality in Sport July 10, 2024 Patrycja Brzozowska, Klaudia Bulska, Konrad Sławek et al.

In spite of the variety of antidepressant drugs available for treating depressive disorder, treatment resistant depression (TRD) is still prevalent among the population. Despite being used mainly in anesthesia, and mostly phased out by more modern anesthetics, ketamine shows potential when it comes to depressive disorder treatment. We've set out to investigate the the relevant body of work to...

Effects of Low-Dose Ketamine Infusion on the Positive and Negative Domains of Hopelessness and Suicidal Thoughts.

The Journal of Clinical Psychiatry July 8, 2024 Wei-Chen Lin, Mu-Hong Chen, Tung-Ping Su et al. 4 citations

Background: Low-dose ketamine infusion has been demonstrated to exert antisuicidal effects on patients with treatment-resistant depression (TRD) and strong suicidal ideation. Although evidence suggests an association between hopelessness and suicidality, very few studies have investigated the antihopelessness effects of ketamine. Methods: This study included 84 patients with TRD and strong...

DOI: 10.4088/JCP.24m15257 (opens in new tab) Full text (opens in new tab) Mental health Ketamine therapy Suicide prevention Depression treatment +1